Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Innovation Action · Running

GENE-BOOST Gene therapy Enhancement through Novel Engineering in Biomanufacturing On Sustainable Technologies

Coordinator
Association Genethon, France
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€6.6m
Total cost
—
Partners
10 organisations in 7 countries
Type
Innovation Action
Grant agreement
101288700

What the project is doing

In the project's own words, from its summary on CORDIS.

AAV-based gene therapies are promising strategies for patients with life-threatening genetic disorders by restoring gene function in along-term effect reversing disease state. The domain of gene therapy is still facing development challenges at the source of extremelyhigh costs of these drugs on the market today, representing several million euros/dollars per dose, which still highly limits patientaccess to these therapies.

This project aims at developing novel tools for second generation processes enabling a significant impact on the development andmonitoring of gene therapy manufacturing processes. The new tools should help to raise productivity by a factor of 100 compared tofirst generation processes that enabled current clinical trials. The ambition of the project relies on combining different expertise to provide innovative process and analytical technologies for themajor critical parameters that influence the production of viral particles and eventually of AAV vectors, previously identified by theconsortium.

A part of the project will be dedicated to the improvement of the upstream part of the process. Development of next generationsolutions to monitor and improve cell culture conditions will allow a deep characterization of cell culture parameters with theobjective of being able to control and to adapt the parameters during the process. Another major challenge in AAV based gene therapy manufacturing is the purification steps to ensure product quality and safety.

Optimizing the purification steps of the DSP will be also a big improvement in the field, with major outputs such as time and costreduction. Eventually, data collected from all monitored parameters for the DSP will feed a digital twin for comprehensive modeling to predictand optimize bioprocess performance, better monitor operations and facilitate decision making.

Who is involved

OrganisationCityCountryRole
Association GenethonEvryFranceCoordinator
LevacellsBrusselsBelgiumParticipant
Vsb - Technical University of OstravaOstrava PorubaCzechiaParticipant
Sartorius Stedim Biotech GmbHGottingenGermanyParticipant
future8 gGmbHSt. IngbertGermanyParticipant
Lomartov SLBurjassotSpainParticipant
Commissariat a L Energie Atomique Et Aux Energies AlternativesParisFranceParticipant
Thales Services Numeriques SASVelizy VillacoublayFranceParticipant
Nova Id Fct - Associacao Para a Inovacao E Desenvolvimento Da FctCaparicaPortugalParticipant
Sartorius Bia Separations, Separacijske Tehnologije, D.o.o.AjdovscinaSloveniaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI